{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:09:16Z","timestamp":1788041356680,"version":"build-2784847793"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Obes Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Overweight and obesity are increasingly common in people with type 1 diabetes mellitus (T1DM). This narrative review synthesizes current evidence on the epidemiology and mechanisms linking excess adiposity with T1DM, the obesity-associated burden of complications, and approaches to obesity management in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Excess adiposity is now frequent in people with T1DM, approaching general-population prevalence, and obesity may also increase the risk of incident T1DM. In T1DM, weight gain reflects intersecting drivers, including intensive insulin therapy, hypoglycemia-related compensatory intake and activity avoidance, obesity-related insulin resistance, and overlapping genetic\/hormonal determinants. Across multiple cohorts, higher adiposity is associated with poorer glycemic control and increased risk of cardiovascular events and mortality, as well as higher risks of retinopathy, diabetic kidney disease, and neuropathy. Evidence to guide treatment in T1DM remains limited. Lifestyle approaches require individualization to minimize hypoglycemia and ketosis. RCTs of adjunct liraglutide demonstrate weight loss and insulin-sparing effects but signal dose-dependent risks of hypoglycemia and ketosis. Early RCTs with semaglutide and tirzepatide suggest substantial weight loss and improved glycemic metrics in selected settings, with vigilance for ketosis. Sodium-glucose cotransporter-2 inhibitors have shown modest HbA1c reductions with small but clinically meaningful weight loss in T1DM; however, they are associated with an increased risk of diabetic ketoacidosis. Bariatric surgery yields large weight loss but only modest glycemic benefit and carries risk of metabolic instability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Obesity is a common, clinically important comorbidity in T1DM, linked to poorer glycemic outcomes and complications. Longer-term, T1DM-specific RCTs are needed to guide weight management and define the benefit-risk of emerging therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13679-026-00693-9","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:11:10Z","timestamp":1771643470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Obesity in Type 1 Diabetes: Moving Beyond the \u201cLean\u201d Disease Paradigm to Understand Risk, Complications, and Treatment"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-472X","authenticated-orcid":false,"given":"Anastasios","family":"Tentolouris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1352","authenticated-orcid":false,"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0505-0395","authenticated-orcid":false,"given":"Evangelos","family":"Fousteris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"693_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 11th edn. Brussels, Belgium. 2025. Available at: https:\/\/diabetesatlas.org."},{"issue":"11","key":"693_CR2","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","volume":"9","author":"B Van der Schueren","year":"2021","unstructured":"Van der Schueren B, Ellis D, Faradji RN, Al-Ozairi E, Rosen J, Mathieu C. Obesity in people living with type 1 diabetes. The Lancet Diabetes & Endocrinology. 2021;9(11):776\u201385. https:\/\/doi.org\/10.1016\/S2213-8587(21)00246-1.","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"3","key":"693_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41366-023-01429-8","volume":"48","author":"MTW Kueh","year":"2024","unstructured":"Kueh MTW, Chew NWS, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes. 2024;48(3):289\u2013301. https:\/\/doi.org\/10.1038\/s41366-023-01429-8.","journal-title":"Int J Obes"},{"key":"693_CR4","doi-asserted-by":"publisher","first-page":"890833","DOI":"10.3389\/fendo.2022.890833","volume":"13","author":"S Ciezki","year":"2022","unstructured":"Ciezki S, Kurpiewska E, Bossowski A, Glowinska-Olszewska B. Multi-Faceted influence of obesity on type 1 diabetes in Children - From disease pathogenesis to complications. Front Endocrinol (Lausanne). 2022;13:890833. https:\/\/doi.org\/10.3389\/fendo.2022.890833.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"693_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jpeds.2015.05.046","volume":"167","author":"SN DuBose","year":"2015","unstructured":"DuBose SN, Hermann JM, Tamborlane WV, Beck RW, Dost A, DiMeglio LA, et al. Obesity in youth with type 1 diabetes in Germany, Austria, and the united States. J Pediatr. 2015;167(3):627\u201332. https:\/\/doi.org\/10.1016\/j.jpeds.2015.05.046.","journal-title":"J Pediatr"},{"key":"693_CR6","doi-asserted-by":"publisher","unstructured":"Lee EY, Lee YH, Jin SM, Yang HK, Jung CH, Park CY, et al. Differential association of body mass index on glycemic control in type 1 diabetes. Diabetes Metab Res Rev. 2017;33(1). https:\/\/doi.org\/10.1002\/dmrr.2815.","DOI":"10.1002\/dmrr.2815"},{"issue":"6","key":"693_CR7","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1111\/dom.15545","volume":"26","author":"T Nystrom","year":"2024","unstructured":"Nystrom T, Andersson Franko M, Ludvigsson J, Lind M, Persson M. Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes. Diabetes Obes Metab. 2024;26(6):2509\u201312. https:\/\/doi.org\/10.1111\/dom.15545.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"693_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa032782","volume":"352","author":"S Tesfaye","year":"2005","unstructured":"Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341\u201350. https:\/\/doi.org\/10.1056\/NEJMoa032782.","journal-title":"N Engl J Med"},{"issue":"2","key":"693_CR9","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.1016\/j.orcp.2013.03.007","volume":"8","author":"SA Price","year":"2014","unstructured":"Price SA, Gorelik A, Fourlanos S, Colman PG, Wentworth JM. Obesity is associated with retinopathy and macrovascular disease in type 1 diabetes. Obes Res Clin Pract. 2014;8(2):e178\u2013182. https:\/\/doi.org\/10.1016\/j.orcp.2013.03.007.","journal-title":"Obes Res Clin Pract"},{"issue":"2","key":"693_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12020-019-02047-z","volume":"66","author":"R Laiginhas","year":"2019","unstructured":"Laiginhas R, Madeira C, Lopes M, Neves JS, Barbosa M, Rosas V, et al. Risk factors for prevalent diabetic retinopathy and proliferative diabetic retinopathy in type 1 diabetes. Endocrine. 2019;66(2):201\u20139. https:\/\/doi.org\/10.1007\/s12020-019-02047-z.","journal-title":"Endocrine"},{"key":"693_CR11","doi-asserted-by":"publisher","unstructured":"Habte-Asres HH, Stedman M, Forbes A, Karalliedde J, Wheeler DC, Heald AH. Incidence and risk factors for chronic kidney disease in individuals with type 1 diabetes: A population-based study in Salford, Manchester. Diabet Med. 2025;e70175. https:\/\/doi.org\/10.1111\/dme.70175.","DOI":"10.1111\/dme.70175"},{"issue":"3","key":"693_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00592-022-01850-x","volume":"59","author":"R Franceschi","year":"2022","unstructured":"Franceschi R, Mozzillo E, Di Candia F, Rosanio FM, Leonardi L, Liguori A, et al. A systematic review of the prevalence, risk factors and screening tools for autonomic and diabetic peripheral neuropathy in children, adolescents and young adults with type 1 diabetes. Acta Diabetol. 2022;59(3):293\u2013308. https:\/\/doi.org\/10.1007\/s00592-022-01850-x.","journal-title":"Acta Diabetol"},{"issue":"13","key":"693_CR13","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra2311526","volume":"390","author":"C Manrique-Acevedo","year":"2024","unstructured":"Manrique-Acevedo C, Hirsch IB, Eckel RH. Prevention of cardiovascular disease in type 1 diabetes. N Engl J Med. 2024;390(13):1207\u201317. https:\/\/doi.org\/10.1056\/NEJMra2311526.","journal-title":"N Engl J Med"},{"issue":"38","key":"693_CR14","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1093\/eurheartj\/ehaf304","volume":"46","author":"Y Wei","year":"2025","unstructured":"Wei Y, Andersson T, Tuomi T, Nystrom T, Carlsson S. Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality. Eur Heart J. 2025;46(38):3776\u201386. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf304.","journal-title":"Eur Heart J"},{"issue":"7","key":"693_CR15","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.2337\/dc18-1446","volume":"42","author":"J Edqvist","year":"2019","unstructured":"Edqvist J, Rawshani A, Adiels M, Bjorck L, Lind M, Svensson AM, et al. BMI, mortality, and cardiovascular outcomes in type 1 diabetes: findings against an obesity paradox. Diabetes Care. 2019;42(7):1297\u2013304. https:\/\/doi.org\/10.2337\/dc18-1446.","journal-title":"Diabetes Care"},{"issue":"1","key":"693_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12933-021-01340-4","volume":"20","author":"EB Parente","year":"2021","unstructured":"Parente EB, Harjutsalo V, Forsblom C, Groop PH, FinnDiane Study G. The impact of central obesity on the risk of hospitalization or death due to heart failure in type 1 diabetes: a 16-year cohort study. Cardiovasc Diabetol. 2021;20(1):153. https:\/\/doi.org\/10.1186\/s12933-021-01340-4.","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"693_CR17","doi-asserted-by":"publisher","first-page":"e2032","DOI":"10.1210\/clinem\/dgaa015","volume":"105","author":"VN Shah","year":"2020","unstructured":"Shah VN, Bailey R, Wu M, Foster NC, Pop-Busui R, Katz M, et al. Risk factors for cardiovascular disease (CVD) in adults with type 1 diabetes: findings from prospective Real-life T1D exchange registry. J Clin Endocrinol Metab. 2020;105(5):e2032\u20132038. https:\/\/doi.org\/10.1210\/clinem\/dgaa015.","journal-title":"J Clin Endocrinol Metab"},{"key":"693_CR18","doi-asserted-by":"publisher","first-page":"112956","DOI":"10.1016\/j.diabres.2025.112956","volume":"229","author":"T Kasahara","year":"2025","unstructured":"Kasahara T, Nishikage S, Hirota Y, Nakatsuji M, Shuichiro S, Yamamoto A, et al. Overweight and macrovascular complications in type 1 diabetes: A nationwide registry study (J\u2013DREAMS). Diabetes Res Clin Pract. 2025;229:112956. https:\/\/doi.org\/10.1016\/j.diabres.2025.112956.","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"693_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(24)00316-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"693_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/M22-3078","volume":"176","author":"M Fang","year":"2023","unstructured":"Fang M, Jeon Y, Echouffo-Tcheugui JB, Selvin E. Prevalence and management of obesity in U.S. adults with type 1 diabetes. Ann Intern Med. 2023;176(3):427\u20139. https:\/\/doi.org\/10.7326\/M22-3078.","journal-title":"Ann Intern Med"},{"issue":"4","key":"693_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.24875\/RIC.20000498","volume":"73","author":"RN Faradji-Hazan","year":"2021","unstructured":"Faradji-Hazan RN, Valenzuela-Lara M, Diaz-Barriga Menchaca AP, Almeda-Valdes P, Antonio-Villa NE, Vidrio-Velazquez M, et al. Type 1 diabetes care in Mexico: an analysis of the RENACED-DT1 national registry. Rev Invest Clin. 2021;73(4):222\u201330. https:\/\/doi.org\/10.24875\/RIC.20000498.","journal-title":"Rev Invest Clin"},{"issue":"10481","key":"693_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"Collaborators GBDAB","year":"2025","unstructured":"Collaborators GBDAB. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):813\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(25)00355-1.","journal-title":"Lancet"},{"key":"693_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00508-018-1434-9","volume":"131","author":"P Fellinger","year":"2019","unstructured":"Fellinger P, Fuchs D, Wolf P, Heinze G, Luger A, Krebs M, et al. Overweight and obesity in type 1 diabetes equal those of the general population. Wien Klin Wochenschr. 2019;131:55\u201360. https:\/\/doi.org\/10.1007\/s00508-018-1434-9.","journal-title":"Wien Klin Wochenschr"},{"issue":"8","key":"693_CR24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/dia.2021.0003","volume":"23","author":"A Lavens","year":"2021","unstructured":"Lavens A, Nobels F, De Block C, Oriot P, Verhaegen A, Chao S, et al. Effect of an integrated, multidisciplinary nationwide approach to type 1 diabetes care on metabolic outcomes: an observational real-world study. Diabetes Technol Ther. 2021;23(8):565\u201376. https:\/\/doi.org\/10.1089\/dia.2021.0003.","journal-title":"Diabetes Technol Ther"},{"key":"693_CR25","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.diabres.2017.01.012","volume":"126","author":"KE Minges","year":"2017","unstructured":"Minges KE, Whittemore R, Weinzimer SA, Irwin ML, Redeker NS, Grey M. Correlates of overweight and obesity in 5529 adolescents with type 1 diabetes: the T1D exchange clinic registry. Diabetes Res Clin Pract. 2017;126:68\u201378. https:\/\/doi.org\/10.1016\/j.diabres.2017.01.012.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"693_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1399-5448.2009.00519.x","volume":"11","author":"LL Liu","year":"2010","unstructured":"Liu LL, Lawrence JM, Davis C, Liese AD, Pettitt DJ, Pihoker C, et al. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes. 2010;11(1):4\u201311. https:\/\/doi.org\/10.1111\/j.1399-5448.2009.00519.x.","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"693_CR27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1111\/pedi.12730","volume":"19","author":"C Maffeis","year":"2018","unstructured":"Maffeis C, Birkebaek NH, Konstantinova M, Schwandt A, Vazeou A, Casteels K, et al. Prevalence of underweight, overweight, and obesity in children and adolescents with type 1 diabetes: data from the international SWEET registry. Pediatr Diabetes. 2018;19(7):1211\u201320. https:\/\/doi.org\/10.1111\/pedi.12730.","journal-title":"Pediatr Diabetes"},{"issue":"7","key":"693_CR28","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/ijo.2009.97","volume":"33","author":"TJ Wilkin","year":"2009","unstructured":"Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes (Lond). 2009;33(7):716\u201326. https:\/\/doi.org\/10.1038\/ijo.2009.97.","journal-title":"Int J Obes (Lond)"},{"issue":"7","key":"693_CR29","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s001250100548","volume":"44","author":"TJ Wilkin","year":"2001","unstructured":"Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia. 2001;44(7):914\u201322. https:\/\/doi.org\/10.1007\/s001250100548.","journal-title":"Diabetologia"},{"issue":"7","key":"693_CR30","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/dom.14022","volume":"22","author":"R Buzzetti","year":"2020","unstructured":"Buzzetti R, Zampetti S, Pozzilli P. Impact of obesity on the increasing incidence of type 1 diabetes. Diabetes Obes Metab. 2020;22(7):1009\u201313. https:\/\/doi.org\/10.1111\/dom.14022.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"693_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1464-5491.2004.01368.x","volume":"22","author":"P Betts","year":"2005","unstructured":"Betts P, Mulligan J, Ward P, Smith B, Wilkin T. Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the \u201caccelerator hypothesis\u201d (2). Diabet Med. 2005;22(2):144\u201351. https:\/\/doi.org\/10.1111\/j.1464-5491.2004.01368.x.","journal-title":"Diabet Med"},{"issue":"1","key":"693_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1464-5491.2010.03160.x","volume":"28","author":"KC Verbeeten","year":"2011","unstructured":"Verbeeten KC, Elks CE, Daneman D, Ong KK. Association between childhood obesity and subsequent type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2011;28(1):10\u20138. https:\/\/doi.org\/10.1111\/j.1464-5491.2010.03160.x.","journal-title":"Diabet Med"},{"issue":"1","key":"693_CR33","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1038\/s41467-022-29932-y","volume":"13","author":"TG Richardson","year":"2022","unstructured":"Richardson TG, Crouch DJM, Power GM, Morales-Berstein F, Hazelwood E, Fang S, et al. Childhood body size directly increases type 1 diabetes risk based on a lifecourse Mendelian randomization approach. Nat Commun. 2022;13(1):2337. https:\/\/doi.org\/10.1038\/s41467-022-29932-y.","journal-title":"Nat Commun"},{"issue":"8","key":"693_CR34","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/obr.12858","volume":"20","author":"K Hidayat","year":"2019","unstructured":"Hidayat K, Zou SY, Shi BM. The influence of maternal body mass index, maternal diabetes mellitus, and maternal smoking during pregnancy on the risk of childhood-onset type 1 diabetes mellitus in the offspring: systematic review and meta-analysis of observational studies. Obes Rev. 2019;20(8):1106\u201320. https:\/\/doi.org\/10.1111\/obr.12858.","journal-title":"Obes Rev"},{"issue":"2","key":"693_CR35","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/ije\/dyx266","volume":"47","author":"MC Magnus","year":"2018","unstructured":"Magnus MC, Olsen SF, Granstrom C, Lund-Blix NA, Svensson J, Johannesen J, et al. Paternal and maternal obesity but not gestational weight gain is associated with type 1 diabetes. Int J Epidemiol. 2018;47(2):417\u201326. https:\/\/doi.org\/10.1093\/ije\/dyx266.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"693_CR36","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","volume":"16","author":"DL Eizirik","year":"2020","unstructured":"Eizirik DL, Pasquali L, Cnop M. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol. 2020;16(7):349\u201362. https:\/\/doi.org\/10.1038\/s41574-020-0355-7.","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"693_CR37","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.numecd.2019.06.008","volume":"29","author":"A Alderisio","year":"2019","unstructured":"Alderisio A, Bozzetto L, Franco L, Riccardi G, Rivellese AA, Annuzzi G. Long-term body weight trajectories and metabolic control in type 1 diabetes patients on insulin pump or multiple daily injections: a 10-year retrospective controlled study. Nutr Metab Cardiovasc Dis. 2019;29(10):1110\u20137. https:\/\/doi.org\/10.1016\/j.numecd.2019.06.008.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"7","key":"693_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2337\/diacare.11.7.567","volume":"11","author":"Weight gain associated","year":"1988","unstructured":"Weight gain associated. With intensive therapy in the diabetes control and complications trial. The DCCT research group. Diabetes Care. 1988;11(7):567\u201373. https:\/\/doi.org\/10.2337\/diacare.11.7.567.","journal-title":"Diabetes Care"},{"issue":"3","key":"693_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1210\/endrev\/bnae032","volume":"46","author":"M Apostolopoulou","year":"2025","unstructured":"Apostolopoulou M, Lambadiari V, Roden M, Dimitriadis GD. Insulin resistance in type 1 diabetes: pathophysiological, clinical, and therapeutic relevance. Endocr Rev. 2025;46(3):317\u201348. https:\/\/doi.org\/10.1210\/endrev\/bnae032.","journal-title":"Endocr Rev"},{"issue":"5","key":"693_CR40","doi-asserted-by":"publisher","first-page":"823","DOI":"10.4239\/wjd.v15.i5.823","volume":"15","author":"T Koufakis","year":"2024","unstructured":"Koufakis T, Patoulias D, Zografou I, Papanas N, Popovic DS. Drawing lines in the sand: the growing threat of obesity in type 1 diabetes. World J Diabetes. 2024;15(5):823\u20137. https:\/\/doi.org\/10.4239\/wjd.v15.i5.823.","journal-title":"World J Diabetes"},{"key":"693_CR41","doi-asserted-by":"publisher","first-page":"630712","DOI":"10.1155\/2014\/630712","volume":"2014","author":"W Luczynski","year":"2014","unstructured":"Luczynski W, Fendler W, Ramatowska A, Szypowska A, Szadkowska A, Mlynarski W, et al. Polymorphism of the FTO gene influences body weight in children with type 1 diabetes without severe obesity. Int J Endocrinol. 2014;2014:630712. https:\/\/doi.org\/10.1155\/2014\/630712.","journal-title":"Int J Endocrinol"},{"issue":"2","key":"693_CR42","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2337\/dc17-0961","volume":"41","author":"MJ Redondo","year":"2018","unstructured":"Redondo MJ, Geyer S, Steck AK, Sosenko J, Anderson M, Antinozzi P, et al. TCF7L2 genetic variants contribute to phenotypic heterogeneity of type 1 diabetes. Diabetes Care. 2018;41(2):311\u20137. https:\/\/doi.org\/10.2337\/dc17-0961.","journal-title":"Diabetes Care"},{"issue":"5","key":"693_CR43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1210\/er.2017-00191","volume":"39","author":"KD Corbin","year":"2018","unstructured":"Corbin KD, Driscoll KA, Pratley RE, Smith SR, Maahs DM, Mayer-Davis EJ, et al. Obesity in type 1 diabetes: Pathophysiology, clinical Impact, and mechanisms. Endocr Rev. 2018;39(5):629\u201363. https:\/\/doi.org\/10.1210\/er.2017-00191.","journal-title":"Endocr Rev"},{"key":"693_CR44","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3389\/fendo.2020.00568","volume":"11","author":"M Wang","year":"2020","unstructured":"Wang M, Tan Y, Shi Y, Wang X, Liao Z, Wei P. Diabetes and sarcopenic obesity: Pathogenesis, Diagnosis, and treatments. Front Endocrinol (Lausanne). 2020;11:568. https:\/\/doi.org\/10.3389\/fendo.2020.00568.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"693_CR45","doi-asserted-by":"publisher","first-page":"112399","DOI":"10.1016\/j.diabres.2025.112399","volume":"227","author":"A Milluzzo","year":"2025","unstructured":"Milluzzo A, Quaranta G, Manuella L, Sceusa G, Bosco G, Giacomo Barbagallo FD, et al. Sarcopenia in type 1 diabetes mellitus: a systematic review. Diabetes Res Clin Pract. 2025;227:112399. https:\/\/doi.org\/10.1016\/j.diabres.2025.112399.","journal-title":"Diabetes Res Clin Pract"},{"key":"693_CR46","doi-asserted-by":"publisher","unstructured":"Christou MA, Christou PA, Katsarou DN, Georga EI, Kyriakopoulos C, Markozannes G, et al. Effect of body weight on glycaemic indices in people with type 1 diabetes using continuous glucose monitoring. J Clin Med. 2024;13(17). https:\/\/doi.org\/10.3390\/jcm13175303.","DOI":"10.3390\/jcm13175303"},{"issue":"5","key":"693_CR47","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4103\/ijem.ijem_294_22","volume":"27","author":"H Dabas","year":"2023","unstructured":"Dabas H, Sarin J, Madhu SV. Insulin adherence in adolescents with type 1 diabetes mellitus. Indian J Endocrinol Metab. 2023;27(5):394\u20137. https:\/\/doi.org\/10.4103\/ijem.ijem_294_22.","journal-title":"Indian J Endocrinol Metab"},{"issue":"10","key":"693_CR48","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.2337\/diacare.17.10.1178","volume":"17","author":"WH Polonsky","year":"1994","unstructured":"Polonsky WH, Anderson BJ, Lohrer PA, Aponte JE, Jacobson AM, Cole CF. Insulin omission in women with IDDM. Diabetes Care. 1994;17(10):1178\u201385. https:\/\/doi.org\/10.2337\/diacare.17.10.1178.","journal-title":"Diabetes Care"},{"issue":"2","key":"693_CR49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/dom.70288","volume":"28","author":"L Anagnostopoulou","year":"2026","unstructured":"Anagnostopoulou L, Liarakos AL, Ntanasis-Stathopoulos I, Briasoulis A, Tentolouris A. Continuous glucose monitoring and microvascular complications in diabetes: bridging glycemic metrics with clinical outcomes. Diabetes Obes Metab. 2026;28(2):840\u20139. https:\/\/doi.org\/10.1111\/dom.70288.","journal-title":"Diabetes Obes Metab"},{"key":"693_CR50","doi-asserted-by":"publisher","first-page":"100542","DOI":"10.1016\/j.ensci.2024.100542","volume":"38","author":"N Piccolo","year":"2025","unstructured":"Piccolo N, Wiggers A, Koubek EJ, Feldman EL. Neuropathy and the metabolic syndrome. eNeurologicalSci. 2025;38:100542. https:\/\/doi.org\/10.1016\/j.ensci.2024.100542.","journal-title":"eNeurologicalSci"},{"key":"693_CR51","doi-asserted-by":"publisher","first-page":"205435811769866","DOI":"10.1177\/2054358117698669","volume":"4","author":"CP Kovesdy","year":"2017","unstructured":"Kovesdy CP, Furth SL, Zoccali C. World kidney day steering C. Obesity and kidney disease: hidden consequences of the epidemic. Can J Kidney Health Dis. 2017;4:2054358117698669. https:\/\/doi.org\/10.1177\/2054358117698669.","journal-title":"Can J Kidney Health Dis"},{"issue":"1","key":"693_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-025-02635-6","volume":"24","author":"R Risi","year":"2025","unstructured":"Risi R, Amendolara R, Pantano AL, Fassino V, D\u2019Onofrio L, Coraggio L, et al. Cardiac autonomic neuropathy is associated with ectopic fat distribution in autoimmune but not in type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):74. https:\/\/doi.org\/10.1186\/s12933-025-02635-6.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"693_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025;393(7):683\u201398. https:\/\/doi.org\/10.1056\/NEJMra2412865.","journal-title":"N Engl J Med"},{"issue":"8","key":"693_CR54","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.cgh.2024.09.038","volume":"23","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Khalil SM, Villela-Nogueira CA, Mantovani A. Global epidemiology and characteristics of metabolic dysfunction-associated steatotic liver disease in type 1 diabetes mellitus: an updated systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2025;23(8):1308-1319 e1317. https:\/\/doi.org\/10.1016\/j.cgh.2024.09.038.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"693_CR55","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057\u201382. https:\/\/doi.org\/10.2337\/dci24-0094.","journal-title":"Diabetes Care"},{"issue":"11","key":"693_CR56","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"E En Li Cho","year":"2023","unstructured":"En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138\u201348. https:\/\/doi.org\/10.1136\/gutjnl-2023-330110.","journal-title":"Gut"},{"issue":"5","key":"693_CR57","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1097\/HEP.0000000000001211","volume":"82","author":"A Unalp-Arida","year":"2025","unstructured":"Unalp-Arida A, Ruhl CE. Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data. Hepatology. 2025;82(5):1256\u201373. https:\/\/doi.org\/10.1097\/HEP.0000000000001211.","journal-title":"Hepatology"},{"issue":"5","key":"693_CR58","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/MEG.0000000000002741","volume":"36","author":"TH Shen","year":"2024","unstructured":"Shen TH, Wu CH, Lee YW, Chang CC. Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12\u201379 years. Eur J Gastroenterol Hepatol. 2024;36(5):636\u201345. https:\/\/doi.org\/10.1097\/MEG.0000000000002741.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"693_CR59","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s00125-025-06597-y","volume":"69","author":"NM Dimitropoulou","year":"2026","unstructured":"Dimitropoulou NM, Beran M, Eussen S, Dingena CF, Dagnelie PC, van der Kallen CJH, et al. Liver fat content is not elevated in people with type 1 diabetes: the Maastricht study. Diabetologia. 2026;69(2):364\u201373. https:\/\/doi.org\/10.1007\/s00125-025-06597-y.","journal-title":"Diabetologia"},{"key":"693_CR60","doi-asserted-by":"publisher","first-page":"112465","DOI":"10.1016\/j.diabres.2025.112465","volume":"229","author":"E Maddaloni","year":"2025","unstructured":"Maddaloni E, Zerunian M, Cardinale V, Zurru A, Amendolara R, Luvera D, et al. Liver disease in people with latent autoimmune diabetes in adults (LADA): A cross-sectional study using magnetic resonance elastography. Diabetes Res Clin Pract. 2025;229:112465. https:\/\/doi.org\/10.1016\/j.diabres.2025.112465.","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"693_CR61","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00198-025-07495-0","volume":"36","author":"S Ferrari","year":"2025","unstructured":"Ferrari S, Akesson KE, Al-Daghri N, Biver E, Chandran M, Chevalley T, et al. Bone microstructure and TBS in diabetes: what have we learned? A narrative review. Osteoporos Int. 2025;36(7):1115\u201328. https:\/\/doi.org\/10.1007\/s00198-025-07495-0.","journal-title":"Osteoporos Int"},{"issue":"Supplement1","key":"693_CR62","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.2337\/dc26-S004","volume":"49","author":"American Diabetes Association Professional Practice Committee for D. 4","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for D. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in Diabetes-2026. Diabetes Care. 2026;49(Supplement1):S61\u201388. https:\/\/doi.org\/10.2337\/dc26-S004.","journal-title":"Diabetes Care"},{"issue":"10","key":"693_CR63","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2337\/dc15-0783","volume":"38","author":"DR Weber","year":"2015","unstructured":"Weber DR, Haynes K, Leonard MB, Willi SM, Denburg MR. Type 1 diabetes is associated with an increased risk of fracture across the life span: a population-based cohort study using the health improvement network (THIN). Diabetes Care. 2015;38(10):1913\u201320. https:\/\/doi.org\/10.2337\/dc15-0783.","journal-title":"Diabetes Care"},{"key":"693_CR64","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.diabres.2018.07.032","volume":"144","author":"N Sanjeevi","year":"2018","unstructured":"Sanjeevi N, Lipsky LM, Nansel TR. Greater inflammation and adiposity are associated with lower bone mineral density in youth with type 1 diabetes. Diabetes Res Clin Pract. 2018;144:10\u20136. https:\/\/doi.org\/10.1016\/j.diabres.2018.07.032.","journal-title":"Diabetes Res Clin Pract"},{"key":"693_CR65","doi-asserted-by":"publisher","first-page":"112114","DOI":"10.1016\/j.diabres.2025.112114","volume":"223","author":"R Risi","year":"2025","unstructured":"Risi R, Amendolara R, Balena A, Watanabe M, Masi D, Fassino V, et al. Osteocalcin is inversely associated with worse adipose tissue distribution and cardiovascular risk in autoimmune diabetes. Diabetes Res Clin Pract. 2025;223:112114. https:\/\/doi.org\/10.1016\/j.diabres.2025.112114.","journal-title":"Diabetes Res Clin Pract"},{"key":"693_CR66","doi-asserted-by":"publisher","unstructured":"Sperkowska BM, Chrustek A, Gryn-Rynko A, Proszowska A. Dietary interventions for adults with type 1 diabetes: clinical Outcomes, guideline Alignment, and research Gaps-A scoping review. Nutrients. 2025;17(21). https:\/\/doi.org\/10.3390\/nu17213349.","DOI":"10.3390\/nu17213349"},{"key":"693_CR67","doi-asserted-by":"publisher","unstructured":"Leow ZZX, Guelfi KJ, Davis EA, Jones TW, Fournier PA. The glycaemic benefits of a very-low-carbohydrate ketogenic diet in adults with type 1 diabetes mellitus May be opposed by increased hypoglycaemia risk and dyslipidaemia. Diabet Med. 2018. https:\/\/doi.org\/10.1111\/dme.13663.","DOI":"10.1111\/dme.13663"},{"issue":"3","key":"693_CR68","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/dom.14911","volume":"25","author":"D Igudesman","year":"2023","unstructured":"Igudesman D, Crandell J, Corbin KD, Zaharieva DP, Addala A, Thomas JM, et al. Weight management in young adults with type 1 diabetes: the advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results. Diabetes Obes Metab. 2023;25(3):688\u201399. https:\/\/doi.org\/10.1111\/dom.14911.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"693_CR69","doi-asserted-by":"publisher","first-page":"e0194987","DOI":"10.1371\/journal.pone.0194987","volume":"13","author":"JL Turton","year":"2018","unstructured":"Turton JL, Raab R, Rooney KB. Low-carbohydrate diets for type 1 diabetes mellitus: A systematic review. PLoS ONE. 2018;13(3):e0194987. https:\/\/doi.org\/10.1371\/journal.pone.0194987.","journal-title":"PLoS ONE"},{"issue":"5","key":"693_CR70","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(17)30014-1","volume":"5","author":"MC Riddell","year":"2017","unstructured":"Riddell MC, Gallen IW, Smart CE, Taplin CE, Adolfsson P, Lumb AN, et al. Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol. 2017;5(5):377\u201390. https:\/\/doi.org\/10.1016\/S2213-8587(17)30014-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"693_CR71","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41574-022-00756-6","volume":"19","author":"MC Riddell","year":"2023","unstructured":"Riddell MC, Peters AL. Exercise in adults with type 1 diabetes mellitus. Nat Rev Endocrinol. 2023;19(2):98\u2013111. https:\/\/doi.org\/10.1038\/s41574-022-00756-6.","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"693_CR72","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/dme.14064","volume":"37","author":"P Narendran","year":"2020","unstructured":"Narendran P, Greenfield S, Troughton J, Doherty Y, Quann N, Thompson C, et al. Development of a group structured education programme to support safe exercise in people with type 1 diabetes: the EXTOD education programme. Diabet Med. 2020;37(6):945\u201352. https:\/\/doi.org\/10.1111\/dme.14064.","journal-title":"Diabet Med"},{"issue":"3","key":"693_CR73","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","volume":"49","author":"E Melson","year":"2025","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ. What is the pipeline for future medications for obesity? Int J Obes (Lond). 2025;49(3):433\u201351. https:\/\/doi.org\/10.1038\/s41366-024-01473-y.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"693_CR74","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/dia.2018.0384","volume":"21","author":"NC Foster","year":"2019","unstructured":"Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016\u20132018. Diabetes Technol Ther. 2019;21(2):66\u201372. https:\/\/doi.org\/10.1089\/dia.2018.0384.","journal-title":"Diabetes Technol Ther"},{"key":"693_CR75","doi-asserted-by":"publisher","first-page":"108973","DOI":"10.1016\/j.diabres.2021.108973","volume":"178","author":"A Welters","year":"2021","unstructured":"Welters A, Tittel SR, Laubner K, Laimer M, Tschope D, Mader JK, et al. Long-term trends of BMI and cardiometabolic risk factors among adults with type 1 diabetes: an observational study from the German\/Austrian DPV registry. Diabetes Res Clin Pract. 2021;178:108973. https:\/\/doi.org\/10.1016\/j.diabres.2021.108973.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"693_CR76","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13679-025-00654-8","volume":"14","author":"G Argyrakopoulou","year":"2025","unstructured":"Argyrakopoulou G, Gitsi E, Dalamaga M, Kokkinos A. Obesity and the Gut-Brain axis in type 1 diabetes mellitus: Terra incognita? Curr Obes Rep. 2025;14(1):61. https:\/\/doi.org\/10.1007\/s13679-025-00654-8.","journal-title":"Curr Obes Rep"},{"key":"693_CR77","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70394","author":"A Tentolouris","year":"2026","unstructured":"Tentolouris A, Ntanasis-Stathopoulos I. If treating obesity with GLP-1-based therapies protects the heart, could it also prevent cancer or improve cancer outcomes? The case for randomized trials. Diabetes Obes Metab. 2026. https:\/\/doi.org\/10.1111\/dom.70394.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"693_CR78","doi-asserted-by":"publisher","first-page":"109271","DOI":"10.1016\/j.jdiacomp.2026.109271","volume":"40","author":"MI Stefanou","year":"2026","unstructured":"Stefanou MI, Tentolouris A, Panagiotopoulos E, Theodorou A, Mengel A, Athanasaki A, et al. Effects of GLP-1 receptor agonists on vascular dementia: a systematic review and meta-analysis. J Diabetes Complications. 2026;40(3):109271. https:\/\/doi.org\/10.1016\/j.jdiacomp.2026.109271.","journal-title":"J Diabetes Complications"},{"issue":"1","key":"693_CR79","doi-asserted-by":"publisher","first-page":"e70140","DOI":"10.1111\/eci.70140","volume":"56","author":"A Tentolouris","year":"2026","unstructured":"Tentolouris A, Ntanasis-Stathopoulos I, Filippatos C, Terpos E, Kastritis E, Duque ER, et al. GLP-1 receptor agonists in patients with MGUS: A real-world propensity-matched study. Eur J Clin Invest. 2026;56(1):e70140. https:\/\/doi.org\/10.1111\/eci.70140.","journal-title":"Eur J Clin Invest"},{"issue":"10","key":"693_CR80","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.2337\/dc16-0691","volume":"39","author":"C Mathieu","year":"2016","unstructured":"Mathieu C, Zinman B, Hemmingsson JU, Woo V, Colman P, Christiansen E, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702\u201310. https:\/\/doi.org\/10.2337\/dc16-0691.","journal-title":"Diabetes Care"},{"issue":"10","key":"693_CR81","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2337\/dc16-0690","volume":"39","author":"B Ahren","year":"2016","unstructured":"Ahren B, Hirsch IB, Pieber TR, Mathieu C, Gomez-Peralta F, Hansen TK, et al. Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial. Diabetes Care. 2016;39(10):1693\u2013701. https:\/\/doi.org\/10.2337\/dc16-0690.","journal-title":"Diabetes Care"},{"issue":"3","key":"693_CR82","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","volume":"4","author":"TF Dejgaard","year":"2016","unstructured":"Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, et al. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology. 2016;4(3):221\u201332. https:\/\/doi.org\/10.1016\/S2213-8587(15)00436-2.","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"6","key":"693_CR83","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2337\/dc15-1136","volume":"39","author":"ND Kuhadiya","year":"2016","unstructured":"Kuhadiya ND, Dhindsa S, Ghanim H, Mehta A, Makdissi A, Batra M, et al. Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care. 2016;39(6):1027\u201335. https:\/\/doi.org\/10.2337\/dc15-1136.","journal-title":"Diabetes Care"},{"issue":"4","key":"693_CR84","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/dom.13911","volume":"22","author":"TF Dejgaard","year":"2020","unstructured":"Dejgaard TF, Schmidt S, Frandsen CS, Vistisen D, Madsbad S, Andersen HU, et al. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial-a randomized, double-blinded, placebo-controlled trial. Diabetes Obes Metab. 2020;22(4):492\u2013500. https:\/\/doi.org\/10.1111\/dom.13911.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"693_CR85","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1111\/dom.14090","volume":"22","author":"H Ghanim","year":"2020","unstructured":"Ghanim H, Batra M, Green K, Abuaysheh S, Hejna J, Makdissi A, et al. Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab. 2020;22(10):1742\u201352. https:\/\/doi.org\/10.1111\/dom.14090.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"693_CR86","doi-asserted-by":"publisher","first-page":"EVIDoa2500173","DOI":"10.1056\/EVIDoa2500173","volume":"4","author":"VN Shah","year":"2025","unstructured":"Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, et al. Semaglutide in adults with type 1 diabetes and obesity. NEJM Evid. 2025;4(8):EVIDoa2500173. https:\/\/doi.org\/10.1056\/EVIDoa2500173.","journal-title":"NEJM Evid"},{"issue":"4","key":"693_CR87","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","volume":"31","author":"MR Pasqua","year":"2025","unstructured":"Pasqua MR, Tsoukas MA, Kobayati A, Aboznadah W, Jafar A, Haidar A. Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial. Nat Med. 2025;31(4):1239\u201345. https:\/\/doi.org\/10.1038\/s41591-024-03463-z.","journal-title":"Nat Med"},{"key":"693_CR88","doi-asserted-by":"publisher","DOI":"10.1177\/15209156251362497","author":"J Mertens","year":"2025","unstructured":"Mertens J, De Winter HT, Dirinck E, Francque S, De Block C. Real-World evidence of the effect of adjunctive semaglutide on weight Change, glycemic Control, and metabolic Dysfunction-Associated steatotic liver disease in people with type 1 diabetes. Diabetes Technol Ther. 2025. https:\/\/doi.org\/10.1177\/15209156251362497.","journal-title":"Diabetes Technol Ther"},{"key":"693_CR89","doi-asserted-by":"publisher","first-page":"111593","DOI":"10.1016\/j.diabres.2024.111593","volume":"209","author":"BA Grassi","year":"2024","unstructured":"Grassi BA, Teresa Onetto M, Sanchez C, Tapia N, Mena F. Effect of low dose semaglutide in people with type 1 diabetes and excess weight. Diabetes Res Clin Pract. 2024;209:111593. https:\/\/doi.org\/10.1016\/j.diabres.2024.111593.","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"693_CR90","doi-asserted-by":"publisher","first-page":"e15377","DOI":"10.1111\/dme.15377","volume":"41","author":"R Frampton","year":"2024","unstructured":"Frampton R, Snaith JR, Hocking S, Holmes-Walker J, Olsen N, Greenfield JR. Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): study protocol of a phase 2 double-blinded randomised placebo-controlled trial. Diabet Med. 2024;41(10):e15377. https:\/\/doi.org\/10.1111\/dme.15377.","journal-title":"Diabet Med"},{"key":"693_CR91","unstructured":"Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes (T1-DISCO.) Available at: https:\/\/clinicaltrials.gov\/study\/NCT05819138?tab=study. Last accessed: Feb 2026."},{"key":"693_CR92","unstructured":"Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care (SEMA-AP). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05205928#study-plan. Last accessed: Feb 2026."},{"key":"693_CR93","unstructured":"Trial of Semaglutide for Diabetic Kidney Disease in. Type 1 Diabetes (RT1D). Available at: https:\/\/clinicaltrials.gov\/study\/NCT05822609#study-plan. Last accessed: Feb 2026."},{"key":"693_CR94","doi-asserted-by":"publisher","unstructured":"Snaith JR, Frampton R, Samocha-Bonet D, Greenfield JR. Tirzepatide in adults with type 1 diabetes: A phase 2 randomized Placebo-Controlled clinical trial. Diabetes Care. 2025. https:\/\/doi.org\/10.2337\/dc25-2379.","DOI":"10.2337\/dc25-2379"},{"key":"693_CR95","doi-asserted-by":"publisher","unstructured":"Patoulias D, Teperikidis E, Popovic DS, Karakasis P, Koufakis T. Tirzepatide as adjunct to insulin for the treatment of type 1 diabetes. Eur J Intern Med. 2025:106624. https:\/\/doi.org\/10.1016\/j.ejim.2025.106624","DOI":"10.1016\/j.ejim.2025.106624"},{"key":"693_CR96","unstructured":"A Study of Tirzepatide (LY3298176.) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06914895#study-plan. Last accessed: Feb 2026."},{"issue":"6","key":"693_CR97","doi-asserted-by":"publisher","first-page":"e3334","DOI":"10.1002\/dmrr.3334","volume":"36","author":"YS Liu","year":"2020","unstructured":"Liu YS, Chen CN, Chen ZG, Peng Y, Lin XP, Xu LL. Vascular and metabolic effects of Metformin added to insulin therapy in patients with type 1 diabetes: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2020;36(6):e3334. https:\/\/doi.org\/10.1002\/dmrr.3334.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"693_CR98","doi-asserted-by":"publisher","first-page":"9884","DOI":"10.1038\/s41467-025-65951-1","volume":"16","author":"JR Snaith","year":"2025","unstructured":"Snaith JR, Olsen N, Evans J, Kowalski GM, Bruce CR, Samocha-Bonet D, et al. Effect of Metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial. Nat Commun. 2025;16(1):9884. https:\/\/doi.org\/10.1038\/s41467-025-65951-1.","journal-title":"Nat Commun"},{"issue":"1","key":"693_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MED.0000000000000841","volume":"31","author":"M Freeby","year":"2024","unstructured":"Freeby M, Lane K. Treating obesity in type 1 diabetes mellitus - review of efficacy and safety. Curr Opin Endocrinol Diabetes Obes. 2024;31(1):1\u20137. https:\/\/doi.org\/10.1097\/MED.0000000000000841.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"693_CR100","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","volume":"21","author":"RE Ratner","year":"2004","unstructured":"Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204\u201312. https:\/\/doi.org\/10.1111\/j.1464-5491.2004.01319.x.","journal-title":"Diabet Med"},{"key":"693_CR101","doi-asserted-by":"publisher","unstructured":"Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health. 2019;16(16). https:\/\/doi.org\/10.3390\/ijerph16162965.","DOI":"10.3390\/ijerph16162965"},{"issue":"12","key":"693_CR102","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.2337\/dc18-1087","volume":"41","author":"P Dandona","year":"2018","unstructured":"Dandona P, Mathieu C, Phillip M, Hansen L, Tschope D, Thoren F, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552\u20139. https:\/\/doi.org\/10.2337\/dc18-1087.","journal-title":"Diabetes Care"},{"issue":"9","key":"693_CR103","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/dom.14060","volume":"22","author":"C Mathieu","year":"2020","unstructured":"Mathieu C, Rudofsky G, Phillip M, Araki E, Lind M, Arya N, et al. Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial. Diabetes Obes Metab. 2020;22(9):1516\u201326. https:\/\/doi.org\/10.1111\/dom.14060.","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"693_CR104","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1111\/dom.14144","volume":"22","author":"C Mathieu","year":"2020","unstructured":"Mathieu C, Dandona P, Birkenfeld AL, Hansen TK, Iqbal N, Xu J, et al. Benefit\/risk profile of Dapagliflozin 5\u00a0mg in the DEPICT-1 and \u2013\u20092 trials in individuals with type 1 diabetes and body mass index >\/=27 kg\/m(2). Diabetes Obes Metab. 2020;22(11):2151\u201360. https:\/\/doi.org\/10.1111\/dom.14144.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"693_CR105","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care. 2018;41(12):2560\u20139. https:\/\/doi.org\/10.2337\/dc18-1749.","journal-title":"Diabetes Care"},{"issue":"24","key":"693_CR106","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","volume":"377","author":"SK Garg","year":"2017","unstructured":"Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1708337.","journal-title":"N Engl J Med"},{"issue":"9","key":"693_CR107","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.2337\/dc18-0343","volume":"41","author":"JB Buse","year":"2018","unstructured":"Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, et al. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care. 2018;41(9):1970\u201380. https:\/\/doi.org\/10.2337\/dc18-0343.","journal-title":"Diabetes Care"},{"issue":"9","key":"693_CR108","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2337\/dc18-0342","volume":"41","author":"T Danne","year":"2018","unstructured":"Danne T, Cariou B, Banks P, Brandle M, Brath H, Franek E, et al. HbA(1c) and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care. 2018;41(9):1981\u201390. https:\/\/doi.org\/10.2337\/dc18-0342.","journal-title":"Diabetes Care"},{"issue":"11","key":"693_CR109","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.2337\/dc20-0924","volume":"43","author":"AL Peters","year":"2020","unstructured":"Peters AL, McGuire DK, Danne T, Kushner JA, Rodbard HW, Dhatariya K, et al. Diabetic ketoacidosis and related events with sotagliflozin added to insulin in adults with type 1 diabetes: a pooled analysis of the inTandem 1 and 2 studies. Diabetes Care. 2020;43(11):2713\u201320. https:\/\/doi.org\/10.2337\/dc20-0924.","journal-title":"Diabetes Care"},{"issue":"2","key":"693_CR110","doi-asserted-by":"publisher","first-page":"e000245","DOI":"10.1136\/bmjph-2023-000245","volume":"2","author":"K Peri","year":"2024","unstructured":"Peri K, Eisenberg M. Review on obesity management: bariatric surgery. BMJ Public Health. 2024;2(2):e000245. https:\/\/doi.org\/10.1136\/bmjph-2023-000245.","journal-title":"BMJ Public Health"},{"key":"693_CR111","doi-asserted-by":"publisher","first-page":"525909","DOI":"10.3389\/fendo.2020.525909","volume":"11","author":"E Korakas","year":"2020","unstructured":"Korakas E, Kountouri A, Raptis A, Kokkinos A, Lambadiari V. Bariatric surgery and type 1 diabetes: unanswered questions. Front Endocrinol (Lausanne). 2020;11:525909. https:\/\/doi.org\/10.3389\/fendo.2020.525909.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Current Obesity Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00693-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13679-026-00693-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13679-026-00693-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:36:03Z","timestamp":1781634963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13679-026-00693-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1007\/s13679-026-00693-9","relation":{},"ISSN":["2162-4968"],"issn-type":[{"value":"2162-4968","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11"}}